Health TrialsbyHealthPanel

Local Spraying of GM-CSF Via Bronchoscopy in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis

ConditionPulmonary Alveolar Proteinosis
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorJiuwu Bai

About this trial

This study aims to explore a new therapeutic approach: the feasibility, safety and preliminary efficacy of directly spraying GM-CSF into the airway through bronchoscopy for the treatment of aPAP.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age: 18 to 60 years old;

Disqualifiers

Secondary PAP (such as secondary to blood diseases, etc.);

Patients with obvious pulmonary fibrosis, emphysema or irreversible lung function impairment;

Patients in the acute exacerbation stage;

Patients with other lung diseases (such as active pulmonary tuberculosis, bronchiectasis with purulent infection or other chronic infections; Have severe asthma, chronic bronchospasm, etc.

Trial design

Design model

Single group

Treatments tested in this trial

  • GM-CSF (granulocyte-macrophage colony-stimulating factor)

    Drug

    Bronchoscopy under general anesthesia or sedation; The predetermined dose of recombinant GM-CSF was dissolved in normal saline. The diseased lung segments were located through bronchoscopy and the liquid medicine was sprayed.

Treatment groups

10 Participants
are divided into 1 treatment group
Group A: Spraying GM-CSFExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Chest HRCT

Time frame
12 weeks

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Jiuwu Bai

Lead sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Sponsor institution

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: